Relationship between therapy and anti-tau antibody levels.

<p>A. Anti-tau antibodies levels in CSF in treated and untreated MS patients. There were differences between the subgroup of patients with therapy and those without therapy (p<0.05) or between the control group and patients without therapy (p<0.01) in the CSF anti-tau levels. B. Intrathecal synthesis of anti-tau antibodies in treated and untreated MS patients. The treated patients and untreated ones had significantly elevated intrathecal synthesis of anti-tau antibodies compared to those in the control group (treated patients vs. controls p<0.001; untreated patients vs. controls p<0.001). C. Avidity of anti-tau antibodies in CSF in treated and untreated MS patients. CSF anti-tau avidities were significantly higher in MS patients without therapy than the controls (p<0.005). There were no differences between treated MS patients and untreated MS ones or controls. Levels and avidities of serum anti-tau antibodies did not differ between the MS subgroups and controls (figure not shown). Abbreviations are explained in the <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0027476#pone-0027476-g001" target="_blank">Fig. 1</a> and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0027476#pone-0027476-g002" target="_blank">2</a>.